Promoter and Institutional shareholding remains unchanged, indicating a lack of confidence from smart money.

Public shareholding increased by 3.56%, suggesting retail investors are buying despite no backing from insiders or institutions.

In a sector where both Promoter and Institutional holdings are stagnant, Krebs Biochemicals is not aligning with the broader sector trends, which may indicate potential weakness.